I would like to talk about the list of schedule 1. Mrs. Perkins, you say in your third recommendation that eligible pharmaceuticals should not be limited to the list in schedule 1 because those that are most needed are not on the list.
Mr. Elliott, you have also recommended to eliminate this schedule 1. I did not take part in the drafting of this legislation but I suppose there would have been a long debate before coming to an agreement on the list. There must have been some kind of consensus.
I wonder how that agreement was achieved when we know that things happen very quickly in R&D. Certainly, new drugs are created regularly. So, should we get rid of that list of schedule 1? Is there any danger in doing that? Would there be any problems? Is that the solution to really implement the legislation?